title: Lessons from trial-based cost-effectiveness analyses of mental health interventions: why uncertainty about the outcome, estimate and willingness to pay matters.
abstract: The principal aim of this article is to share lessons learned by the authors while conducting economic evaluations, using clinical trial data, of mental health interventions. These lessons are quite general and have clear relevance for pharmacoeconomic studies. In addition, we explore how net benefit regression can be used to enhance consideration of key issues when conducting an economic evaluation based on clinical trial data. The first study we discuss found that cost-effectiveness results varied markedly based on the choice of both the patient outcome and the willingness to pay for more of that outcome. The importance of willingness to pay was also highlighted in the results from the second study. Even with a set willingness-to-pay value, most of the time the probability that the new treatment was cost effective was not 100%. In the third study, the cost effectiveness of the new treatment varied by patient characteristics. These observations have important implications for pharmacoeconomic studies. Namely, analysts must carefully consider choice of patient outcome, willingness to pay, patient heterogeneity and the statistical uncertainty inherent in the data. Net benefit regression is a useful technique for exploring these crucial issues when undertaking an economic evaluation using patient-level data on both costs and effects.
authors: Centre for Research on Inner City Health, The Keenan Research Centre in Li Ka Shing Knowledge Institute of St. Michaels Hospital, Toronto, Ontario, Canada.
authors: Jeffrey S
authors: JS
authors: Hoch
authors: Carolyn S
authors: CS
authors: Dewa
mesh_terms: D000465:Algorithms; D002986:Clinical Trials as Topic; D003156:Community Mental Health Services / Q000191:economics; D003362:Cost-Benefit Analysis / Q000379:methods / Q000706:statistics & numerical data; D003419:Crisis Intervention / Q000191:economics; D017850:Economics, Pharmaceutical; D006801:Humans; D001523:Mental Disorders / Q000191:economics / Q000628:therapy*; D019057:Quality-Adjusted Life Years; D012044:Regression Analysis; D012050:Rehabilitation, Vocational / Q000191:economics; D012114:Residential Treatment / Q000191:economics; D016896:Treatment Outcome